Nektar Therapeutics (LTS:0UNL) Debt-to-Equity : 0.90 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Nektar Therapeutics Debt-to-Equity?

Nektar Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $19.37 Mil. Nektar Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $94.71 Mil. Nektar Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $126.71 Mil. Nektar Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was 0.90.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nektar Therapeutics's Debt-to-Equity or its related term are showing as below:

LTS:0UNL' s Debt-to-Equity Range Over the Past 10 Years
Min: -909.95 Med: 0.31 Max: 73.27
Current: 0.9

During the past 13 years, the highest Debt-to-Equity Ratio of Nektar Therapeutics was 73.27. The lowest was -909.95. And the median was 0.31.

LTS:0UNL's Debt-to-Equity is ranked worse than
85.29% of 1074 companies
in the Biotechnology industry
Industry Median: 0.15 vs LTS:0UNL: 0.90

Nektar Therapeutics Debt-to-Equity Historical Data

The historical data trend for Nektar Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Debt-to-Equity Chart

Nektar Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.29

0.14

0.21

0.36

0.90

Nektar Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.53	0.63	0.76	0.90	0.90

Competitive Comparison of Nektar Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Nektar Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nektar Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Debt-to-Equity falls into.

Nektar Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nektar Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(19.259	+	98.517)	/	130.987
	=	0.90

Nektar Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(19.368	+	94.71)	/	126.705
	=	0.90

Nektar Therapeutics (LTS:0UNL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Nektar Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nektar Therapeutics (LTS:0UNL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (LTS:0UNL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

NKTR:USA ITH:Germany

Address

455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158

Website

https://www.nektar.com

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Nektar Therapeutics (LTS:0UNL) Headlines

No Headlines